Sharpe ratio
0.73Return earned for the risk taken.
Moderate
Moderate risk-adjusted returns. The reward for risk has been average.
+14.11%1Y Absolute Return
-0.24%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus OptionFund 5Y annualised return | ₹10,72,072 | ₹7,32,612 | ₹3,39,460 | +15.27% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.18
₹1 Lakh since launch₹1.18 Lakh
Fund age13.9 yrs
Fund information
Scheme code118758
ISININF204K01I27
BenchmarkNIFTY 500 Total Return Index
CategoryEquity Scheme - Sectoral/ Thematic
Expense ratio—
Exit load—
Minimum SIP—
Return comparison
152nd / 932 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +176.98% | — | — |
| 3M | +9.67% | — | — |
| 6M | +16.38% | — | — |
| 1Y | +14.11% | — | +4.16% |
| 3Y | +18.57% | — | +12.54% |
| 5Y | +15.27% | — | +10.04% |
| 10Y | +16.29% | — | — |
| Since Launch | +17.53% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
1.07Return earned while limiting downside risk.
Good
Good downside protection with strong returns.
Standard deviation
12.51%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
0.73How well the fund rewarded investors relative to its biggest decline.
Good
Good return relative to the drawdowns experienced.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 38 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.31% |
| Lupin Ltd | Healthcare | Equity | 7.25% |
| Divi's Laboratories Ltd | Healthcare | Equity | 6.52% |
| Cipla Ltd | Healthcare | Equity | 6.03% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 5.3% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 5.01% |
| Mankind Pharma Ltd. | Healthcare | Equity | 3.74% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 3.62% |
| Ajanta Pharma Ltd | Healthcare | Equity | 3.41% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 3.15% |
Fund management
AM
Amber Singhania
Since 2026 · Prior to joining the Nippon India AMC, he was associated with Asian Markets Securities Pvt. Ltd.
MMS Finance (Mumbai University)
SA
Sailesh Raj Bhan
Since 2012 · Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Mr. Bhan is an MBA (Finance) and CFA.
KI
Kinjal Desai
Since 2026 · She has been working with Nippon India Mutual Fund since year, 2012
Ms. Desai has done B.A (Economics), MSc. (Economics) and has cleared CFA Level 1
Compare similar funds
No comparable category funds are available yet.
Summary
A very high-risk equity scheme - sectoral/ thematic fund. Ahead of its category average over 3Y by 6.0 points. Healthcare makes up 97% — trouble in that sector hits the whole fund.
Strengths
- Ahead of its category average over 3Y by 6.0 points.
- Same fund manager for 14+ years — the strategy has not chopped and changed.
- Ranks 152 of 932 in its category over 1 year.
Weaknesses
- None
Ideal investor
- Needs a 5–7+ years horizon to ride out its very high risk level.
- Good fit for SIPs — spreading purchases smooths out 12.5% volatility.
Risk drivers
- Healthcare makes up 97% — trouble in that sector hits the whole fund.